Herceptin

Biocon to start selling breast cancer drug in India in February

MUMBAI (Reuters) - Biocon Ltd( BION.NS ) said its generic version of Roche's( ROG.VX ) Herceptin breast cancer treatment would be available to patients in India from the first week of February. Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with U.S.-based Mylan Inc. About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.

Not just India: UK regulator says Roche’s new breast cancer drug too costly

The National Institute for Care and Excellence (NICE) of the UK has rejected Roche’s latest breast cancer drug Perjeta because it is too expensive.

Scientists identify new drug targets for aggressive breast cancer

The scientists discovered that a protein tyrosine phosphatase, called UBASH3B, is overexpressed in one third of TNBC patients.